EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A Review of Population Pharmacokinetic Models and Dosing Algorithms Assessing the Influence of CYP3A5 Genotype and Other Clinical Covariates on Tacrolimus Pharmacokinetics

Riley M Randolph, Sara Jubas, Li Gong, Raman Venkataramanan, Dhrita Khatri, Pamala A Jacobson, David Metz, Daniel J Crona

Clinical Pharmacokinetics · 2026-09 · 65 (9) · 1295-1315

DOI: 10.1007/s40262-026-01673-x ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 20.07.2026. Verfasst von Riley M Randolph und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, 120 Mason Farm Road, CB 7361, G…. Hauptthemen laut MEDLINE: Tacrolimus, Cytochrome P-450 CYP3A, Immunosuppressive Agents, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 149 Literaturangaben. Gefördert von: NIGMS NIH HHS, Medical Research Future Fund, NHGRI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tacrolimus is a narrow therapeutic index drug with wide intrapatient and interpatient pharmacokinetic variability and cytochrome P450 3A5 ( CYP3A5 ) genotype-guided dosing recommendations. This review aimed to evaluate population pharmacokinetic models and dosing algorithms across all treatment settings that analyzed the influence of CYP3A5 genotypic variation plus additional clinical covariates on tacrolimus pharmacokinetics. These effects were mathematically translated and summarized to provide a comparison between models. Changes in apparent clearance warranting tacrolimus dose adjustments were assessed and summarized by relative magnitude and direction. Sixty-eight tacrolimus population pharmacokinetic models were included in this review, including 55 developed for adults and 38 for kidney transplant recipients. The most frequently retained covariates on tacrolimus clearance were CYP3A5 genotype (88%), body size (29%), hematocrit (29%), and days since transplant (28%). The median fold increase in apparent clearance, across all treatments, was 1.64 for CYP3A5 normal and intermediate metabolizer patients compared to poor metabolizer patients. As days since transplant increased, median tacrolimus apparent clearance increased in liver ( n = 6) and lung transplant ( n = 2) models but decreased early post-transplant and then subsequently increased in kidney transplant models ( n = 11). Concomitant administration of tacrolimus with -azole antifungals or Wuzhi capsules was associated with reduced tacrolimus apparent clearance (38% and 31%, respectively), while corticosteroids were associated with a 23% increase in apparent clearance. Based on our analysis, a substantial tacrolimus dose increase (≥ 75%) is required for CYP3A5 normal and intermediate metabolizer patients compared with poor metabolizer patients. Ultimately, these findings can be used to determine optimal personalized tacrolimus doses across a variety of disease states and treatment types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusCytochrome P-450 CYP3AImmunosuppressive AgentsModels, BiologicalHumansGenotypeAlgorithmsKidney TransplantationDose-Response Relationship, DrugAdult

Substanzen

TacrolimusCytochrome P-450 CYP3AImmunosuppressive AgentsCYP3A5 protein, human

Autor:innen und Institutionen

  • Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, 120 Mason Farm Road, CB 7361, Genetic Medicine Building 2090, Chapel Hill, NC, 27599, USA.
  • Department of Biomedical Data Science, Stanford University, Stanford, CA, USA.
  • Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.
  • Cancer Therapies, Stem Cell Medicine, Murdoch Children's Research Institute, Parkville, VIC, Australia.
  • Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia.
  • Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.

Förderung

  • NIGMS NIH HHS
  • Medical Research Future Fund
  • NHGRI NIH HHS
  • National Institute of General Medical Sciences
  • National Human Genome Research Institute

Zitieren

APA

Randolph, R. M., Jubas, S., Gong, L., Venkataramanan, R., Khatri, D., Jacobson, P. A., Metz, D., & Crona, D. J. (2026). A Review of Population Pharmacokinetic Models and Dosing Algorithms Assessing the Influence of CYP3A5 Genotype and Other Clinical Covariates on Tacrolimus Pharmacokinetics. Clinical Pharmacokinetics, 65(9), 1295-1315. https://doi.org/10.1007/s40262-026-01673-x

Vancouver

Randolph RM, Jubas S, Gong L, Venkataramanan R, Khatri D, Jacobson PA, et al. A Review of Population Pharmacokinetic Models and Dosing Algorithms Assessing the Influence of CYP3A5 Genotype and Other Clinical Covariates on Tacrolimus Pharmacokinetics. Clinical Pharmacokinetics. 2026;65(9):1295-1315. doi:10.1007/s40262-026-01673-x

BibTeX
@article{Randolph2026,
  author = {Randolph, Riley M and Jubas, Sara and Gong, Li and Venkataramanan, Raman and Khatri, Dhrita and Jacobson, Pamala A and Metz, David and Crona, Daniel J},
  title = {A Review of Population Pharmacokinetic Models and Dosing Algorithms Assessing the Influence of CYP3A5 Genotype and Other Clinical Covariates on Tacrolimus Pharmacokinetics},
  journal = {Clinical Pharmacokinetics},
  year = {2026},
  volume = {65},
  number = {9},
  pages = {1295--1315},
  doi = {10.1007/s40262-026-01673-x}
}
Kostenlos starten →